The forward P/E of 14.72 is notably below the trailing multiple, indicating that analysts expect earnings to rebound as the company laps divestitures and realizes cost savings. However, the EV/EBITDA of 13.85 is only modestly below PG's 17.11, suggesting that the market still assigns a premium to KMB's cash generation. The 4.5% dividend yield, nearly double PG's, compensates for the lower growth but may signal limited capital appreciation prospects. Investors should monitor whether the forward multiple compresses further if guidance cuts persist.

The gross margin expansion likely reflects a favorable mix shift toward higher-margin Personal Care and K-C Professional segments, as well as the exit of lower-margin tissue businesses. However, the operating margin compression suggests that the company is reinvesting in brand support and supply chain modernization, which may not yet be yielding efficiency gains. Net margin of 8.2% in 2026Q2 is below the 12.2% reported in 2025Q2, highlighting the impact of one-time items and higher interest expense. The sustainability of gross margin gains is questionable given the commodity-linked cost structure, and investors should watch for further input cost inflation.

The sharp decline in ROIC from 9.7% to 4.2% over eight quarters is concerning, as it indicates that the company is generating less profit per dollar of invested capital. This could be due to increased capital expenditure relative to a shrinking revenue base, as well as the impact of divestitures that reduced earnings power. ROE has also been volatile, swinging from 66.6% in 2024Q3 to 18.1% in 2026Q2, which may reflect one-time gains and the thin equity base. The trend suggests that KMB is not efficiently deploying capital, and investors should monitor whether the new segment structure improves capital allocation.

The negative CCC is a sign of operational efficiency, as KMB collects cash from customers before paying suppliers. However, the extended DPO of 116 days may indicate reliance on supplier credit, which could become a risk if suppliers tighten terms. DSO has remained stable around 42 days, while DIO has decreased slightly, suggesting better inventory management. The improvement in CCC from -7 days in 2024Q1 to -21 days in 2026Q2 is notable, but it may be partly due to the shrinking revenue base. Investors should assess whether this efficiency is sustainable or a result of temporary working capital timing.

The significant deleveraging, with D/E dropping from 8.12 to 3.44, suggests that management has prioritized debt reduction, possibly through asset sales and retained earnings. However, the absolute debt level of $6.5 billion remains substantial, and the interest coverage ratio, while adequate, has declined from its peak. The D/EBITDA ratio of 10.60 in 2026Q2 is elevated, indicating that EBITDA has not kept pace with debt reduction. This suggests that the company's earnings power has weakened, and investors should monitor whether coverage deteriorates further if operating margins remain under pressure.

The sub-1.0 current ratio suggests that KMB relies on ongoing cash flow and access to credit markets to meet short-term obligations. The quick ratio of 0.69 further highlights the limited buffer, as inventory is not easily convertible to cash. While the company has a strong credit profile and generates stable cash flow, the thin liquidity position could be vulnerable to a sudden disruption in cash generation or a tightening of credit markets. Investors should monitor whether management builds a larger cash cushion or extends debt maturities to reduce refinancing risk.